TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04718155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: will receive 40 mg atrorvastatin 2 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: will receive 40 mg placebo 2 days
Study: NCT06515197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Music
Description: Participants in this group will listen to pre-selected motivational music tracks for 30 minutes before each basketball training and performance test. This intervention will be conducted three times a week for 12 weeks. The aim is to assess the impact of motivational music on mental energy, mental toughness, psychological skills, mindfulness, athletic identity, and sports performance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Selected Music
Description: Participants in this group will choose their own music to listen to for 30 minutes before each basketball training and performance test. This intervention will be conducted three times a week for 12 weeks. The goal is to determine the effect of self-selected music on mental energy, mental toughness, psychological skills, mindfulness, athletic identity, and sports performance.
Study: NCT05718310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: 25 migraine patients without aura of both genders are randomized to receive a 20-minutes infusion of NTG and/or sterile saline on two days, with at least one week in between

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 25 migraine patients without aura of both genders are randomized to receive a 20-minutes infusion of NTG and/or sterile saline on two days, with at least one week in between
Study: NCT05087485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: digital education in skin cancer diagnostics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: digital education in skin cancer diagnostics
Study: NCT04431817

Intervention type: DEVICE
Intervention: KinetiGait
Description: This device is an Intel RGB depth camera that relays video to gait analysis software. The images will be taken from amputees walking at a self-selected pace on a treadmill.

Intervention type: DEVICE
Intervention: KinetiGait
Description: This device is an Intel RGB depth camera that relays video to gait analysis software. The images will be taken from amputees walking at a self-selected pace on a treadmill.

Intervention type: DEVICE
Intervention: KinetiGait
Description: This device is an Intel RGB depth camera that relays video to gait analysis software. The images will be taken from amputees walking at a self-selected pace on a treadmill.

Intervention type: DEVICE
Intervention: KinetiGait
Description: This device is an Intel RGB depth camera that relays video to gait analysis software. The images will be taken from amputees walking at a self-selected pace on a treadmill.

Intervention type: DEVICE
Intervention: KinetiGait
Description: This device is an Intel RGB depth camera that relays video to gait analysis software. The images will be taken from amputees walking at a self-selected pace on a treadmill.
Study: NCT05494060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride capsule
Description: Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab Injection
Description: Penpulimab Injection 100mg per bottle, 200mg IV Day 1, cycled every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w
Study: NCT04910646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orange peel fermentation
Description: To evaluate whether the fermented orange peel enzyme has the effect of reducing body fat.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo without orange peel fermentation
Study: NCT05741346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX9930
Description: Taken orally at 400 mg twice daily (BID)
Study: NCT04731766

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Citrine 5 % sodium fluoride
Description: Citrine varnish is a 5% sodium fluoride varnish, It was developed to prolong the contact between the tooth surface and fluoride to increase the resistance against caries attack and manage tooth hypersensitivity; the active ingredient of fluoride varnish is mostly 5% sodium fluoride.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: concocted nano-silver fluoride
Description: Nano-silver fluoride (NSF) is a solution which has been introduced as an experimental formulation in which it's stability for three years has been proved by Santos et al. The laboratory synthesis of concocted NSF was carried out in a nano-technology center; Several trials were done until we have reached a successful end product.
Study: NCT06433804

Intervention type: DIAGNOSTIC_TEST
Intervention: HER2 IHC
Description: Immunohistochemistry for HER2

Intervention type: DIAGNOSTIC_TEST
Intervention: HER2 IHC
Description: Immunohistochemistry for HER2
Study: NCT06200298

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block with naropeine [3,75 mg/mL]
Description: Erector spinae plane block Procedure:~* Ultrasound scan with protective sleeve and sterile gel. Research of the thoracic spine process between T8 (for thoracic arthrodesis) and T12 (for lumbar arthrodesis)~* Once the thorny process is identified, horizontal shift to the transverse process.~* When the transverse process is spotted, sagittal rotation of the ultrasound probe~* Skin puncture with an 80 mm hyperechogenic needle in the plane of the ultrasound probe. The needle will be placed in contact with the transverse process~* Injection, after aspiration, of the solution prepared blindly by the anesthesiologist performing the procedure. For the ESPB group, a long-acting local anaesthetic: ropivacaine 3.75 mg/mL, 30 mL.~* Repetition of the gesture for the transverse controlateral process

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESPB with saline 0,9%
Description: Procedure for the Erector spinae plane block Procedure by NaCl 0.9%:~* Ultrasound scan with protective sleeve and sterile gel. Research of the thoracic spine process between T8 (for thoracic arthrodesis) and T12 (for lumbar arthrodesis)~* Once the thorny process is identified, horizontal shift to the transverse process.~* When the transverse process is spotted, sagittal rotation of the ultrasound probe~* Skin puncture with an 80 mm hyperechogenic needle in the plane of the ultrasound probe. The needle will be placed in contact with the transverse process~* Injection, after aspiration, of the solution prepared blindly by the anesthesiologist performing the procedure. For the control group: saline isotonic serum 30 mL.~Repetition of the gesture for the transverse controlateral process
Study: NCT05822453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (1000 mg/m2) will be administered by IV infusion on Day 1and Day 8 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S1 (60 mg/day if body surface area \< 1.25 m2, 80 mg/day if body surface area = 1.25\~1.50 m2) will be administered by PO on Day 1 \~ 14 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab (200 mg) will be administered by IV infusion on Day 1 of each 21-day cycle
Study: NCT06078280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioPumlonary Management System (CPM)
Description: The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG (electrocardiogram), heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
Study: NCT05023395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEE-HU Medicus
Description: This investigational medicinal product (MEE-HU Medicus) is a patented mixture of amino acids and pentose sugar. The mixture according to the invention in particular is suitable as medicine for resistance-breaking of antibiotic resistances of pathogens, in particular for resistance-breaking of multiple antibiotic resistances, a method for decreasing bacterial resistance to antibiotics.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05755490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROWESS
Description: Structured, culturally sensitive behavior change intervention comprised of six video-based or in-person sessions with psychologist or social worker. FitBit is provided by study.
Study: NCT04034550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and urine sampling and blood banking
Description: In routine management, blood and urine will be sampled for each patients and specific analyses carried out. Only blood samples will be banked.
Study: NCT04740892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wash IP
Description: Parent participant will bathe the child participant with the investigational wash at least 3 times per week, but no more than once daily, for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream IP
Description: Parent participant will apply the investigational cream on their child participant twice daily for 4 weeks.
Study: NCT05309434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coach
Description: The coach coordinates the initiation of CPR, communicates feedback device data to assist those performing compressions, communicates average targets for compressions and ventilations and coordinates operations to achieve those values, and communicates with the team to reduce pauses in compressions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coach
Description: The coach coordinates the initiation of CPR, communicates feedback device data to assist those performing compressions, communicates average targets for compressions and ventilations and coordinates operations to achieve those values, and communicates with the team to reduce pauses in compressions.
Study: NCT04717284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-compassion intervention (SCI)
Description: All participants will be asked to recall a recent parenting event they feel ashamed of and type it into a text box provided. Participants in the SCI group will then be instructed to reflect on their recalled parenting event and prompted to think about and write about the event in a self-compassionate manner. The prompt is designed to induce on all of the three key elements of self-compassion described by Neff (2003a): self-kindness; common humanity; and mindfulness. The same instructions will be provided for follow-up period.

Intervention type: OTHER
Group type: OTHER
Intervention: Control condition
Description: All participants will be asked to recall a recent parenting event they feel ashamed of and type it into a text box provided. Participants in the control group will then be instructed to make notes about factual information of the event (e.g. time of day, who was there, the weather, etc.). During the two-week follow-up period, participants in the control group will not take part in any intervention as part of the trial.
Study: NCT05411367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-614
Description: 1 drop in each eye

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 1 drop in each eye
Study: NCT06050954

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab (200mg)
Description: 200mg Pembrolizumab every six weeks via IV infusion.

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab (400mg)
Description: 400mg Pembrolizumab every six weeks via IV infusion.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Monitoring
Description: active surveillance and monitoring via continued serial ctDNA testing and radiographic assessments at regular intervals.
Study: NCT05492188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Operant Conditioning of Cutaneous Reflexes
Description: This is a training intervention in which people with a spinal cord injury are trained to change (increase or decrease) the activity of a certain spinal reflex. By changing this reflex, it is hypothesized that individuals can reduce pain due to spinal cord injury.
Study: NCT04758299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: decision science-based design
Description: decision science-based design explaining actions to take for a negative or positive COVID-19 test
Study: NCT05722054

Intervention type: OTHER
Intervention: Diagnostic tests
Description: Blood smears; rapid diagnostic tests; complete blood counts with differential; leucoconcentration; urine examination; nasal/throat swabs, stool examination.

Intervention type: OTHER
Intervention: Diagnostic tests
Description: Blood smears; rapid diagnostic tests; complete blood counts with differential; leucoconcentration; urine examination; nasal/throat swabs, stool examination.

Intervention type: OTHER
Intervention: Diagnostic tests
Description: Blood smears; rapid diagnostic tests; complete blood counts with differential; leucoconcentration; urine examination; nasal/throat swabs, stool examination.

Intervention type: OTHER
Intervention: Diagnostic tests
Description: Blood smears; rapid diagnostic tests; complete blood counts with differential; leucoconcentration; urine examination; nasal/throat swabs, stool examination.

Intervention type: OTHER
Intervention: Equilibrate diet
Description: Nutritionally-balanced Alimentation
Study: NCT03024177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vapendavir
Description: Vapendavir Tablets, 264 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Vapendavir 264 mg matching tablets
Study: NCT04808622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans-Sodium Crocetinate
Description: TSC given as a one-time IV bolus injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans-Sodium Crocetinate
Description: TSC given as a one-time IV bolus injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans-Sodium Crocetinate
Description: TSC given as a one-time IV bolus injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans-Sodium Crocetinate
Description: TSC given as a one-time IV bolus injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans-Sodium Crocetinate
Description: TSC given as a one-time IV bolus injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo normal saline given as a one-time 7 mL one-time IV bolus injection
Study: NCT06072443

Intervention type: BEHAVIORAL
Intervention: Digital Health Companion (mobile App)
Description: Participants will complete education modules, health literacy evaluations, and PRO assessments in the Digital Health Companion.

Intervention type: BEHAVIORAL
Intervention: Digital Health Companion (mobile App)
Description: Participants will complete education modules, health literacy evaluations, and PRO assessments in the Digital Health Companion.
Study: NCT05325697

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intervention consisting of a multicomponent exercise program combined with an oral nutritional supplement
Description: The multicomponent exercise program to prevent frailty and risk of falls (Vivifrail) was developed by a European expert group co-funded by the ERASMUS+ programm of the European Union. The program consists of a screening and a subsequent 12-week exercise program. The screening classifies individuals into four categories: disabled, frail, pre-frail, or robust and the difficulty of the program's exercises is adapted to the categories and it includes endurance, balance, and resistance training as well as stretching exercises. This exercise program will be combined with an oral nutritional supplement (Moltein®Plus), which was specifically designed to promote muscle health in elderly people. Moltein®Plus is completely balanced oral nutrition supplement made from whey protein fortified with leucine. Enriching dietary protein with leucine allows to maximize muscle protein synthesis rates without calling for very high protein doses, which are difficult to ingest for older individuals.
Study: NCT06321549

Intervention type: OTHER
Intervention: The reference point of minimally invasive mastectomy procedure conducted
Description: November 2018 as a temporal reference point was predicated on the milestone of the medical center's inaugural minimally invasive mastectomy procedure conducted
Study: NCT06026085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skinceuticals skin care product(CE)
Description: Skinceuticals skin care product(CE FERULIC)+routine sun protection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fraxel laser therapy
Description: Fraxel DUAL 1550/1927 Laser System

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fraxel laser therapy
Description: Fraxel DUAL 1550/1927 Laser System

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: 0.9% normal saline+routine sun protection
Study: NCT05975957

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photomodulation Therapy with the Light-Aid system
Description: Patients in the intervention group (FBM) will be submitted to 10 treatment sessions (twice a week/five weeks) with the Light-Aid system (Bright Photomedicine, SP, Brazil), operated in continuous mode, with 100 LEDs of 850nm wave per tip, with application time varying from 4 to 8 minutes. Irradiation parameters will be customized based on pain intensity, skin phototype and Body Mass Index (BMI).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Patients in the placebo group will undergo the same therapeutic protocol as the FBM group using a device with the same appearance as the Light-Aid System, but with inert light emission. In both groups, the treatment will be administered in contact with the skin over the knee, with the patient positioned in dorsal decubitus. The three tips of the device will be positioned horizontally over the anterior region of the knee with the central tip over the patella.
Study: NCT04782388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Description: Study participants will receive Staccato alprazolam at prespecified time-point.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will receive Staccato placebo at prespecified time-point.
Study: NCT05615532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590 (SC)
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590 (SC)
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590 (SC)
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590 (SC)
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590 (IV)
Description: Administered IV.
Study: NCT06375889

Intervention type: OTHER
Intervention: blood test
Description: During the routine blood test of the patient, 5 more tubes of 2.7 milliliters (mL) will be collected to make Platelet Activation Analysis

Intervention type: OTHER
Intervention: blood test
Description: During the routine blood test of the patient, 5 more tubes of 2.7 milliliters (mL) will be collected to make Platelet Activation Analysis
Study: NCT05221463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-assisted breastfeeding training
Description: Breastfeeding training was given to the experimental group for 3 days by means of the training material prepared by the training nurse of the hospital about breast milk and breastfeeding and routinely used by nurses in breast milk training in neonatal units. During the training, mothers were allowed to watch breast milk and breastfeeding training videos. On the third day after the training, feedback was received from the applications in the video regarding the knowledge and skills of the mother, and the mother's questions were answered.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The hospital's routine general breastfeeding training
Description: The control group was given the hospital's general breastfeeding training for 3 days by means of the training material prepared by the training nurse of the hospital about breast milk and breastfeeding and used routinely by nurses in breast milk training in neonatal units, and the questions of the mother were answered. The mothers in this group performed the routine breastfeeding process and no other interventions were made.
Study: NCT05828043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-domain intervention
Description: Each session comprises of 45 minutes physical fitness activities targeting on muscle strength, balance, and flexibility; 1-hour cognitive training primarily on reasoning and memory exercises; and 15-minute for nutritional advices based on national diet guidelines for older adults
Study: NCT04900922

Intervention type: DEVICE
Intervention: isokinetic dynamometer
Description: We will use an isokinetic dynamometer to conduct the concentric isokinetic fatigue protocol. The start position is shoulder abduction 90°, elbow flexion 90°and range of motion is set from 0 ° (internal rotation) to 90 ° (external rotation) under 120°/s. To calculate maximum torque of shoulder external and internal rotation, the subject will perform maximum isokinetic test 5 times before fatigue. Fatigue protocol include 10 sets, and each set include 32 repetitions with 30 seconds of rest between sets. The fatigue protocol will be stopped under three conditions: 1. the torque decreases 50% of maximum torque three times in one set or 2.rating of perceived exertion (RPE) abrove 15 and players can not perform the fatigue protocol or 3. finish the whole test.
Study: NCT06235931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darcilide +AI (letrozole/anastrozole/Exemestane) + pyrrotinib
Description: Darcilie: 125mg orally once a day, taken for 21 days and stopped for 7 days, 28 days as a cycle.~AI: Letrozole: 2.5mg orally once daily, or anastrozole 1mg orally once daily, or exemestane 25mg orally once daily.~Pyrrotinib: Initial dose of 240mg in the first week, if diarrhea and other side effects can be tolerated, 320 mg can be added in the second week, once a day, oral administration within 30 minutes after breakfast, 21 days for 1 cycle~All investigational drugs should be used for disease progression or when patients have an intolerable adverse reaction or are withdrawn from the study for other reasons.~Oral pyrrotinib is recommended along with prophylactic antidiarrheal medication. Antidiarrheal regimen 1: Oral imodium (2 tablets/times, 2 times a day) from the first week, 1 tablet, 2 times a day from the second week. Antidiarrheal regimen 2: montmorillonite powder (3 times a day, 1 pack/time)+ whole intestine sheng (3 pills/time 2 times a day).